Pharmaceutical composition comprising a3 adenosine receptor agonist (ib-meca/cf-101) for treatment of psoriasis

Pharmaceutical composition comprising a3 adenosine receptor agonist (ib-meca/cf-101) for treatment of psoriasis

CN
  • CN 104,173,364 A
  • Filed: 09/06/2010
  • Published: 12/03/2014
  • Est. Priority Date: 09/06/2009
  • Status: Active Application
First Claim
Patent Images

1. the 1-[N of the active component of the amount of about 4mg 6-(3-iodine benzyl)-adenine-9-yl]-β

  • -D-RIBOSE amide (IB-MECA) is in the purposes in psoriatic pharmaceutical composition for the preparation for the treatment of, wherein said pharmaceutical composition is the dosage form comprising as the 4mg IB-MECA administration once a day of active component, or described pharmaceutical composition is the dosage form comprising as twice administration 2mg IB-MECA every day of active component.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×